Jin De, Zhang Yuqin, Zhang Yuehong, Duan Liyun, Zhou Rongrong, Duan Yingyin, Sun Yuting, Lian Fengmei, Tong Xiaolin
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Pharmacol. 2021 Aug 26;12:734151. doi: 10.3389/fphar.2021.734151. eCollection 2021.
Panax ginseng C.A.Mey. has been widely consumed as food/diet supplements from natural sources, and its therapeutic properties have also aroused widespread concern. Therapeutic properties of Panax ginseng C.A.Mey. such as anti-inflammatory, ameliorating chronic inflammation, enhancing the immunity, resisting the oxidation again, and regulating the glucose and lipid metabolism have been widely reported. Recent years, lots of interesting studies have reported the potential use of Panax ginseng C.A.Mey. in the management of DKD. DKD has become the leading cause of end-stage renal disease worldwide, which increases the risk of premature death and poses a serious financial burden. Although DKD is somehow controllable with different drugs such as Angiotensin-Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB) and lowering-glucose agents, modern dietary changes associated with DKD have facilitated research to assess the preventive and therapeutic merits of diet supplements from natural sources as medicine including Panax ginseng C.A.Mey. Findings from many scientific evidences have suggested that Panax ginseng C.A.Mey. can relieve the pathological status in cellular and animal models of DKD. Moreover, a few studies showed that alleviation of clinical phenotype such as reducing albuminuria, serum creatinine and renal anemia in DKD patients after application or consumption of Panax ginseng C.A.Mey.. Therefore, this review aims to discuss the effectiveness of Panax ginseng C.A.Mey. as medicine for targeting pathological phenotypes in DKD from a pharmacological perspective. This review will provide new insights into the potential understanding use of Panax ginseng C.A.Mey. in the management of DKD in clinical settings.
人参已被广泛用作天然来源的食品/膳食补充剂，其治疗特性也引起了广泛关注。人参的治疗特性，如抗炎、改善慢性炎症、增强免疫力、再次抵抗氧化以及调节葡萄糖和脂质代谢等，已被广泛报道。近年来，许多有趣的研究报道了人参在糖尿病肾病管理中的潜在用途。糖尿病肾病已成为全球终末期肾病的主要原因，增加了过早死亡的风险，并带来了严重的经济负担。尽管糖尿病肾病可以通过不同药物如血管紧张素转换酶抑制剂（ACEI）、血管紧张素受体阻滞剂（ARB）和降糖药物在一定程度上得到控制，但与糖尿病肾病相关的现代饮食变化促进了对包括人参在内的天然来源膳食补充剂作为药物的预防和治疗优点的研究。许多科学证据的研究结果表明，人参可以缓解糖尿病肾病细胞和动物模型中的病理状态。此外，一些研究表明，应用或食用人参后，糖尿病肾病患者的临床表型得到改善，如蛋白尿、血清肌酐和肾性贫血减少。因此，本综述旨在从药理学角度探讨人参作为针对糖尿病肾病病理表型的药物的有效性。本综述将为在临床环境中理解人参在糖尿病肾病管理中的潜在用途提供新的见解。
